Press Releases

VitaDAO and Molecule AG partner with Apollo Health Ventures to build the longevity biotech & Web3 ecosystem

Molecule has announced a tripartite partnership with Apollo Health Ventures and VitaDAO.

MicrobioSeq Releases PCR-based Microbial Antibiotic Resistance Gene Analysis Service

MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance gene analysis service to help researchers develop new antimicrobial medicines to address the worldwide threat of antibiotic resistance.

CD Genomics: Bioinformatics-Analysis Division Provides Genotyping Analysis Service for Studying Genetic Variations

CD ComputaBio Launches Homology Modeling Service for Drug Screening and Discovery

As a reliable computational biology service provider based in New York, CD ComputaBio has recently launched homology modeling service to help researchers deeply understand the structure-activity relationship of the target protein, and provide strong support for structure-based rational drug design, protein function research, and protein engineering research. Relying on its professional team and advanced technology, as well as high-quality products and services, CD ComputaBio has gained a solid reputation.

CD ComputaBio Releases Molecular Docking Service for Enzymology Research and Drug Design

CD ComputaBio, a reliable computational biology service provider located in New York, always hammers at researches and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of molecular docking service, which has a wide range of applications in the field of enzymology research and drug design.

Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Sinocompound announces commercial-scale production of QPhos ligand

Sinocompound has today announced production of the phosphine-based QPhos ligand in kilogram quantities for commercial use.

Rho Experts to Present at 5th Annual Gene Therapy for Rare Disorders Conference

Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10. Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed: ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs ü Gene therapy approval examples that highlight key nonclinical considerations

Creative Biogene: A Premier Partner in the Exploration of Pathogenesis of Mitochondrial-Associated Diseases

Creative Biogene has become the premier partner to cooperate in the exploration of the pathogenesis of mitochondrial-associated diseases.

Pronalyse Launches Antibody Drug Conjugates (ADCs) Characterization Service for Drug Discovery

Pronalyse, a new division of Creative Proteomics, is an integrated CRO company with rich experience in providing drug development services for over 10 years. Creative Proteomics Pronalyse recently announced the launch of antibody-drug conjugates (ADCs) characterization service to ensure the safety and effectiveness of ADCs drugs.

Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Microbial Metabolomics Solutions

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.

ERGOMED announces launch of its Rare Disease Innovation Center™

ERGOMED announces launch of its Rare Disease Innovation Center™ Rare Disease Innovation Center to provide strategic guidance and tailored innovative solutions to sponsors focused on rare disease drug development Raleigh, North Carolina, February 28, 2022 – ERGOMED plc (LSE: ERGO) a leading Clinical Research Organization focused on rare disease drug development today announced the establishment of its Rare Disease Innovation Center.

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center Collaboration will provide sponsors with access to industry-leading technology and expertise to optimise rare disease drug development and tackle unmet medical need Bracknell, UK: 28 February 2022 – mdgroup, the leading global provider of personalised clinical study services and technologies, has been selected to provide patient support services to Ergomed’s Rare Disease Innovation Centre.

Rho Awarded NIH-NIAID Contract to Support Clinical Research in Autoimmune Diseases

Research Triangle Park, NC – February 28, 2022 – Rho, a global, full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) for the National Institute of Allergy and Infectious Diseases. As the AD-SCCC, Rho will provide a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This project has been funded $8.3 million in the first year with Federal funds from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00003. This award has the potential to provide a total of over $49 million to the AD-SCCC over the next five years.

AARDEX Group Joins Innovative IT4Anxiety Project

Innovative medication adherence tools in a real-world hospital setting to reduce anxiety in users of mental health services.

ClinOne Names Clinical Research Technology Leader Andrea Valente Chief Executive Officer

As the newly appointed ClinOne CEO, Andrea Valente brings strategic leadership, industry, product and operational experience needed at a pivotal moment in the company’s exponential growth

Creative Bioarray Develops Cell Immortalization Kits and Immortalized Human Cells to Support Immortalized Cell Research

Qvirus Platform Offers Custom Baculovirus Production to Accelerate High-level Gene Expression

DDA platform Provides In Vitro Skin Absorption Test to Support The Studies in Comestics